Literature DB >> 22651113

Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial.

Jordan J Elm1, Yuko Y Palesch, Gary G Koch, Vanessa Hinson, Bernard Ravina, Wenle Zhao.   

Abstract

It is not uncommon to have experimental drugs under different stages of development for a given disease area. Methods are proposed for use when another treatment arm is to be added mid-study to an ongoing clinical trial. Monte Carlo simulation was used to compare potential analytical approaches for pairwise comparisons through a difference in means in independent normal populations including (1) a linear model adjusting for the design change (stage effect), (2) pooling data across the stages, or (3) the use of an adaptive combination test. In the presence of intra-stage correlation (or a non-ignorable fixed stage effect), simply pooling the data will result in a loss of power and will inflate the type I error rate. The linear model approach is more powerful, but the adaptive methods allow for flexibility (re-estimating sample size). The flexibility to add a treatment arm to an ongoing trial may result in cost savings as treatments that become ready for testing can be added to ongoing studies.

Entities:  

Mesh:

Year:  2012        PMID: 22651113      PMCID: PMC3770292          DOI: 10.1080/10543406.2010.528103

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  12 in total

1.  Monitoring a clinical trial with multiple hypotheses concerning the treatment effect on a single primary endpoint.

Authors:  J S Denne; G G Koch
Journal:  Stat Med       Date:  2001-10-15       Impact factor: 2.373

2.  Adaptive sample size calculations in group sequential trials.

Authors:  W Lehmacher; G Wassmer
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

3.  Modification of sample size in group sequential clinical trials.

Authors:  L Cui; H M Hung; S J Wang
Journal:  Biometrics       Date:  1999-09       Impact factor: 2.571

4.  A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.

Authors: 
Journal:  Neurology       Date:  2007-01-02       Impact factor: 9.910

5.  Adaptive group sequential test for clinical trials with changing patient population.

Authors:  Huaibao Feng; Jun Shao; Shein-Chung Chow
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

6.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

7.  Evaluation of experiments with adaptive interim analyses.

Authors:  P Bauer; K Köhne
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

8.  The appropriateness of analysis of variance and multiple-comparison procedures.

Authors:  P C O'Brien
Journal:  Biometrics       Date:  1983-09       Impact factor: 2.571

9.  Statistical methods for a three-period crossover design in which high dose cannot be used first.

Authors:  K E Peace; G G Koch
Journal:  J Biopharm Stat       Date:  1993-03       Impact factor: 1.051

10.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

Authors: 
Journal:  Neurology       Date:  2006-02-15       Impact factor: 9.910

View more
  9 in total

1.  To add or not to add a new treatment arm to a multiarm study: A decision-theoretic framework.

Authors:  Kim May Lee; James Wason; Nigel Stallard
Journal:  Stat Med       Date:  2019-05-21       Impact factor: 2.373

2.  Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.

Authors:  Steffen Ventz; Matteo Cellamare; Giovanni Parmigiani; Lorenzo Trippa
Journal:  Biostatistics       Date:  2018-04-01       Impact factor: 5.899

3.  Inference in response-adaptive clinical trials when the enrolled population varies over time.

Authors:  Massimiliano Russo; Steffen Ventz; Victoria Wang; Lorenzo Trippa
Journal:  Biometrics       Date:  2021-10-21       Impact factor: 1.701

Review 4.  Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice.

Authors:  Dena R Cohen; Susan Todd; Walter M Gregory; Julia M Brown
Journal:  Trials       Date:  2015-04-22       Impact factor: 2.279

5.  Including non-concurrent control patients in the analysis of platform trials: is it worth it?

Authors:  Kim May Lee; James Wason
Journal:  BMC Med Res Methodol       Date:  2020-06-24       Impact factor: 4.615

6.  On model-based time trend adjustments in platform trials with non-concurrent controls.

Authors:  Marta Bofill Roig; Pavla Krotka; Carl-Fredrik Burman; Ekkehard Glimm; Stefan M Gold; Katharina Hees; Peter Jacko; Franz Koenig; Dominic Magirr; Peter Mesenbrink; Kert Viele; Martin Posch
Journal:  BMC Med Res Methodol       Date:  2022-08-15       Impact factor: 4.612

7.  Adding new experimental arms to randomised clinical trials: Impact on error rates.

Authors:  Babak Choodari-Oskooei; Daniel J Bratton; Melissa R Gannon; Angela M Meade; Matthew R Sydes; Mahesh Kb Parmar
Journal:  Clin Trials       Date:  2020-02-17       Impact factor: 2.486

8.  Designs for adding a treatment arm to an ongoing clinical trial.

Authors:  Maxine Bennett; Adrian P Mander
Journal:  Trials       Date:  2020-03-06       Impact factor: 2.279

9.  Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats.

Authors:  Kim May Lee; Louise C Brown; Thomas Jaki; Nigel Stallard; James Wason
Journal:  Trials       Date:  2021-03-10       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.